en · de · es · fr · pt
sr9009-notes.peptides3626.com › Data › Background And Mechanism — 2026 Update

Background And Mechanism — 2026 Update

By Editorial Desk · published 2025-06-30 · last reviewed 2025-07-23 · Data

If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-07-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Related pages on this site

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Regulation, Testing, and Storage

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Reference notes

=== Procedure === A crucible and its lid are pre-weighed after thorough drying. The sample is added to the completely dry crucible and lid and together they are weighed to determine the mass of the sample by difference. The sample is placed in the hot furnace long enough so that complete combustion of the sample occurs. The crucible, lid and ash then are re-weighed.

Cherry juice is a fruit juice consisting of the juice of cherries. It is consumed as a beverage and used as an ingredient in various foods, processed foods and beverages. It is also marketed as a health supplement. It is produced by hot- or cold-pressing cherries, collecting the juice, and then filtering and pasteurizing it.

There was a lingering ambiguity in the general notion of "diabetes", especially as it manifests very differently in diabetes mellitus and in diabetes insipidus. In 1843, William Prout aptly summarized the general notion of diabetes of the time as follows:The term diabetes, implying simply an increased flow of urine, is applicable to any disease in which that symptom is present in a remarkable degree. This general use of the term, however, has caused a great deal of confusion; as a variety of diseases differing altogether in their nature, except in the accidental circumstances of being accompanied by diuresis, or a large flow of urine, have in consequence been confounded with one another. To prevent this confusion in future, I would recommend that the term be restricted to those affections in which the urine is saccharine. Hence I define Diabetes to be a disease in which a saccharine state of the urine is the characteristic symptom.

Sources: en.wikipedia.org

Notes from published material

Cardiac amyloidosis is a subcategory of amyloidosis where there is depositing of the protein amyloid in the heart muscle and sometimes other organs or structures. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function and heart failure. The overall decrease in cardiac function leads to a plethora of symptoms. This multisystem disease was often misdiagnosed, with a definitive diagnosis only during autopsy. Advancements of technologies have led to earlier and more accurate diagnosis. However diagnosis may still be delayed as the disease may remain asymptomatic for years as amyloid deposits in the heart and other organs or tissues. Diagnosis may be delayed further as the disease may be misdiagnosed or confused for other more common conditions that cause heart enlargement (such as hypertension or other forms of heart failure). Cardiac amyloidosis has multiple sub-types including light chain, hereditary transthyretin amyloidosis (due to genetic variants leading to misfolded transthyretin protein depositing in the heart and other tissues), and wild type transthyretin amyloidosis (where misfolded transthyretin builds up in heart muscle and other tissues, but with an absence of any mutations).

Nedaplatin, sold in Japan as Aqupla (see External Links), is a platinum-based chemotherapy agent. It is toxic to DNA, causing damage to DNA, limiting DNA repair and ultimately limiting DNA synthesis, limiting the propagation of cancer cells.

Some research has shown that sea ice diatoms can use an ancient bacterial metabolic pathway known as the Entner−Doudoroff pathway (EDP) to maintain metabolism and energy production during light limitation. The ability of diatoms to use light for energy also depends on air temperature. As it gets colder, the thylakoid membranes within the microalgae plastids can become dense and compact, which influences how certain photosynthetic proteins (such as the proteins necessary for Photosystems I & II) function and self-assemble. Sea ice diatoms can alter the saturation of the fatty acids that compose the thylakoid membranes as temperatures decrease, which can provide more fluidity to these membranes and result in proper folding of photosynthetic proteins at subzero temperatures. As temperatures within brine pockets decrease, organisms that survive within brine pockets produce substances that can help prevent freezing. Some sea ice diatoms can produce specialized ice-binding proteins and extracellular polymeric substances, which can help increase the habitat space available within a brine pocket by preventing ice formation and reducing the freezing temperature of the brine. Decreased temperatures can also reduce the efficiency of important physiological processes within many microorganisms. Psychrophilic diatoms and bacteria have the ability to regulate their production of proteins, DNA, and enzymes required for metabolism to help maintain metabolic efficiency in colder temperatures.

== Ownership and management == Jollibee is owned by the Jollibee Foods Corporation, which is based in Pasig, Philippines. JFC has operated as a franchisor since 1979. JFC also owns other fast food brands in the Philippines, including Chowking, Greenwich Pizza, Red Ribbon Bakeshop, and Mang Inasal, and it operates Burger King franchises.

Sources: en.wikipedia.org

Background from the literature

Inflammation of the thyroid is called thyroiditis, and may cause symptoms of hyperthyroidism or hypothyroidism. Two types of thyroiditis initially present with hyperthyroidism and are sometimes followed by a period of hypothyroidism – Hashimoto's thyroiditis and postpartum thyroiditis. There are other disorders that cause inflammation of the thyroid, and these include subacute thyroiditis, acute thyroiditis, silent thyroiditis, Riedel's thyroiditis and traumatic injury, including palpation thyroiditis. Hashimoto's thyroiditis is an autoimmune disorder (autoimmune disease) in which the thyroid gland is infiltrated by the lymphocytes B cell and T cells. These progressively destroy the thyroid gland. In this way, Hashimoto's thyroiditis may have occurred insidiously, and only be noticed when thyroid hormone production decreases, causing symptoms of hypothyroidism. Hashimoto's is more common in females than males, much more common after the age of 60, and has known genetic risk factors. Also more common in individuals with Hashimoto's thyroiditis are Type 1 diabetes, pernicious anaemia, Addison's disease, and vitiligo. Postpartum thyroiditis occurs sometimes following childbirth. After delivery, the thyroid becomes inflamed and the condition initially presents with a period of hyperthyroidism followed by hypothyroidism and, usually, a return to normal function. The course of the illness takes place over several months, and is characterised by a painless goitre. Antibodies against thyroid peroxidase can be found on testing.

Parliamentary elections were held in Portugal on 8 November 1925. The result was a victory for the Democratic Party, which won 83 of the 163 seats in the Chamber of Deputies and 39 of the 70 seats in the Senate. Following a military coup in 1926 and the subsequent Estado Novo period, the 1925 elections were the last truly multi-party elections in Portugal until the 1975 Constituent Assembly elections.

Copper sulfate is produced industrially by treating copper metal with hot concentrated sulfuric acid or copper oxides with dilute sulfuric acid. For laboratory use, copper sulfate is usually purchased. Copper sulfate can also be produced by slowly leaching low-grade copper ore in air; bacteria may be used to hasten the process. Commercial copper sulfate is usually about 98% pure copper sulfate, and may contain traces of water. Anhydrous copper sulfate is 39.81% copper and 60.19% sulfate by mass, and in its blue, hydrous form, it is 25.47% copper, 38.47% sulfate (12.82% sulfur) and 36.06% water by mass. Four types of crystal size are provided based on its usage: large crystals (10–40 mm), small crystals (2–10 mm), snow crystals (less than 2 mm), and windswept powder (less than 0.15 mm).

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network